Nasdaq Threatens Delisting as Equity Falls Below $2.5M
DARE sits 50% above its 52-week low of $1.27 on light trading volume (0.2× avg).
Summary
Dare Bioscience received a Nasdaq delisting notice on July 13 after stockholders' equity dropped below the required $2.5 million. The company plans to request a hearing, which temporarily stays any suspension, but there is no guarantee of an extension or regaining compliance. This follows a series of capital raises and an expanded stock incentive plan approved in June, yet the equity shortfall persists. With a market cap near $29 million and a cash runway only into Q4 2026, the delisting risk adds immediate pressure to secure financing or boost equity. The hearing request buys time, but failure to regain compliance could force a move to over-the-counter markets, severely limiting liquidity.
At the time of this announcement, DARE was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.4M. The 52-week trading range was $1.27 to $3.78. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.